NCT03933943View on ClinicalTrials.gov

A Study of LY3361237 in Participants With Systemic Lupus Erythematosus

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 21, 2019

Primary Completion Date

February 15, 2021

Study Completion Date

February 15, 2021

Conditions
Lupus Erythematosus, Systemic
Interventions
DRUG

LY3361237

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (9)

16635

Altoona Center For Clinical Research, Duncansville

28210

DJL Clinical Research, PLLC, Charlotte

30046

North Georgia Rheumatology, PC, Lawrenceville

33606

Clinical Research of West Florida, Tampa

33765

Clinical Research of West Florida, Clearwater

36207

Pinnacle Research Group, Anniston

38305

West Tennessee Research Institute, Jackson

44130

Paramount Medical Research, Middleburg Heights

77084

Accurate Clinical Management LLC - Katy, Houston

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03933943 - A Study of LY3361237 in Participants With Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter